Ovarian Neoplasms
Conditions
Interventions
We will investigate samples from 40 patients with advanced or relapsed platinum-sensitive ovarian cancer in retrospective cohort. This is a retrospective cohort study conducted at the Oncoclínicas Pre
V03.175.500
Sponsors
Oncoclinicas do Brasil Serviços Médicos S.A
LOCUS - Anatomia Patologia e Citologia LTDA
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients > 18 years old; diagnosed with high grade serous ovarian cancer; platinum-sensitive; mutant or wild type for germline or somatic HRR genes based on OCPM Next Generation Sequencing (NGS) panels.
Exclusion criteria
Exclusion criteria: Patient that do not accept to sign the informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| This is a retrospective cohort study conducted at the Oncoclínicas Precision Medicine laboratory facilities to technically validate a new HRD test. Specifically, this study aims to verify the concordance of the QIAseq HRD Panel (QIAGEN) with the gold standard HRD test myChoice CDx (Myriad Genetics). As an exploratory objective, we will assess the clinical impact of HRD test results by stratifying patients according to response status to platinum-based regimen and/or PARPi therapy. | — |
Secondary
| Measure | Time frame |
|---|---|
| No secondary outcomes are expected | — |
Countries
Brazil
Contacts
Public ContactLeandro Camara
Oncoclinicas do Brasil Serviços Médicos S.A
Outcome results
None listed